Heartbeam, Inc. - Common Stock (BEAT)
0.6881
-0.0319 (-4.43%)
NASDAQ · Last Trade: Dec 2nd, 12:47 PM EST
Detailed Quote
| Previous Close | 0.7200 |
|---|---|
| Open | 0.7200 |
| Bid | 0.6811 |
| Ask | 0.6880 |
| Day's Range | 0.6808 - 0.7200 |
| 52 Week Range | 0.5400 - 3.480 |
| Volume | 1,187,117 |
| Market Cap | 23.57M |
| PE Ratio (TTM) | 1.464 |
| EPS (TTM) | 0.5 |
| Dividend & Yield | N/A (N/A) |
| 1 Month Average Volume | 6,451,249 |
Chart
About Heartbeam, Inc. - Common Stock (BEAT)
Heartbeam Inc is a healthcare technology company focused on developing innovative solutions for cardiac care. The company specializes in advanced heart monitoring technologies, particularly through its proprietary platform that combines telemedicine with electrocardiogram (ECG) technology. Heartbeam's products aim to provide healthcare professionals and patients with real-time monitoring and analysis of heart health, facilitating early detection of potential issues and improving patient outcomes. By leveraging cutting-edge technology, Heartbeam seeks to enhance the management of cardiovascular diseases and promote more informed healthcare decisions. Read More
News & Press Releases
Join us as we delve into today's session and uncover the stocks that are standing out with unusual volume.
Via Chartmill · December 1, 2025
BioMedNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) Outlines Regulatory Strategy After NSE Decision on ECG Synthesis Software
HeartBeam (NASDAQ: BEAT), a medical technology company developing personalized cardiac-care insights, detailed its strategy following receipt of a Not Substantially Equivalent decision for its 510(k) submission covering its 12-lead ECG Synthesis Software. The Company has been in active discussions with FDA review staff, which have signaled willingness to work toward a constructive resolution. HeartBeam said its VALID-ECG clinical study met endpoints and that remaining FDA concerns may be resolved through revised labeling. To advance the process, the Company plans to pursue multiple parallel paths—including a formal appeal or a 510(k) resubmission—and believes recent interactions indicate a viable path forward under the appeal option, which carries an expected 60-day timeline. HeartBeam will continue providing updates on commercialization and funding plans as regulatory engagement progresses.
Via Investor Brand Network · December 1, 2025
As the regular session of the US market concludes on Friday, let's get an insight into the after-hours session and identify the stocks leading the pack in terms of gains and losses.
Via Chartmill · November 28, 2025
Intrigued by the market activity one hour before the close of the markets on Friday? Uncover the key winners and losers of today's session in our insightful analysis.
Via Chartmill · November 28, 2025
These stocks are making the most noise in today's session. Stay tuned for the latest updates!
Via Chartmill · November 28, 2025
In today's session, there are stocks attracting attention with their unusual volume. Let's take a closer look.
Via Chartmill · November 28, 2025
Today's session on Friday is marked by notable gaps in various stocks. Stay informed with the gap up and gap down stocks in today's session.
Via Chartmill · November 28, 2025
As we await the opening of the US market on Friday, let's delve into the pre-market session and discover the top gainers and losers shaping the early market sentiment.
Via Chartmill · November 28, 2025
The regular session of the US market on Thursday is now over, but let's get a preview of the after-hours session and explore the top gainers and losers driving the post-market movements.
Via Chartmill · November 27, 2025
After the conclusion of the US market's regular session on Wednesday, let's examine the after-hours session and unveil the notable performers among the top gainers and losers.
Via Chartmill · November 26, 2025
HeartBeam, Inc. (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care by providing powerful personalized insights, today announced its regulatory strategy following receipt of a Not Substantially Equivalent (NSE) decision on the Company’s 510(k) submission for its 12-lead Electrocardiogram (ECG) Synthesis Software.
By HeartBeam, Inc. · Via Business Wire · November 26, 2025
In today's session, these stocks are experiencing unusual volume.
Via Chartmill · November 25, 2025
Let's explore the current happenings on the US markets on Monday. Below, you'll find the stocks exhibiting unusual volume in today's session.
Via Chartmill · November 24, 2025
Let's have a look at what is happening on the US markets after the closing bell on Friday. Below you can find the top gainers and losers in today's after hours session.
Via Chartmill · November 21, 2025
The company said it will work with the agency to reach a resolution and expressed confidence in its clinical data.
Via Stocktwits · November 21, 2025
InvestorNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) Poised in the Future of Cardiac Care with Breakthrough Technology
HeartBeam (NASDAQ: BEAT) is on the verge of transforming how atrial fibrillation (“AF”) is detected and managed with its cable-free ECG technology. A recent article discussing this reads, “HeartBeam has developed a credit card-sized device and proprietary synthesis software that can capture heart signals in three dimensions and convert them into a full synthesized 12-lead ECG. By bringing clinical -grade cardiac diagnostics into the hands of patients wherever they are, HeartBeam is positioning itself at the forefront of a revolution in heart health, one that could greatly impact lives, reduce costs, and redefine the future of cardiac care.”
Via Investor Brand Network · November 19, 2025
NetworkNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) Reports Q3 2025 Results as FDA Review Nears Completion and Commercial Readiness Accelerates
HeartBeam (NASDAQ: BEAT) reported third-quarter 2025 results and highlighted continued progress toward commercialization of its 12-lead ECG synthesis software, now in the final stage of FDA 510(k) review with anticipated clearance by year end. The company is advancing commercial readiness, including a new partnership with HeartNexus for 24/7 cardiologist review services, alongside new scientific data presented at AHA Scientific Sessions and HRX Live 2025 and an expanded global IP portfolio of 24 issued patents. For the quarter, R&D expenses were $3.3 million, G&A expenses were $2.0 million, net loss was $5.3 million and cash totaled $1.9 million. HeartBeam will discuss its results and provide a business update during a conference call and webcast on Nov. 13 at 4:30 p.m. ET.
Via Investor Brand Network · November 14, 2025
HeartBeam reports Q3 2025 results, missing EPS estimates. The pre-revenue firm focuses on FDA clearance for its cardiac tech, a key milestone expected by year-end.
Via Chartmill · November 13, 2025
HeartBeam (BEAT) Q3 2025 Earnings Call Transcript
Via The Motley Fool · November 13, 2025
HeartBeam, Inc. (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care by providing powerful personalized insights, has reported its financial and operational results for the third quarter ended September 30, 2025.
By HeartBeam, Inc. · Via Business Wire · November 13, 2025
HeartBeam Inc. (NASDAQ: BEAT) Advances Remote Cardiac Diagnostics with HeartNexus Partnership
HeartBeam (NASDAQ: BEAT), a medical-technology company developing next-generation cardiac diagnostics via its patented 12-Lead ECG synthesis software, has announced a strategic collaboration with HeartNexus ( https://ibn.fm/yyz1i ). The partnership will expand access to cardiologist-level ECG insights for arrhythmia assessment anytime, anywhere. Cardiovascular disease remains the leading cause of mortality worldwide, responsible for an estimated 17.9 million deaths annually according to the World Health Organization ( https://ibn.fm/oQxTL ). ECGs are the most common cardiac test yet standard ECG testing often requires in-clinic visits, specialized…
Via Investor Brand Network · November 13, 2025
HeartBeam (NASDAQ: BEAT) has cemented its position as a vanguard in medical technology, earning multiple prestigious accolades that underscore its groundbreaking contributions to portable ECG innovation. Most notably, the company was recently identified as a Global IP and Technology Leader in Portable Cardiac Diagnostics by PatentVest's "Total Cardiac Intelligence" report, placing it second worldwide in [...]
Via TokenRing AI · November 12, 2025
HeartBeam Inc. (NASDAQ: BEAT) Recognized as a Top Global Innovator in Portable ECG Technology
HeartBeam (NASDAQ: BEAT), a medical-technology company developing advanced electrocardiogram solutions for remote cardiac care, has been recognized as a Global IP and Technology Leader in Portable Cardiac Diagnostics by PatentVest’s “Total Cardiac Intelligence” report ( https://ibn.fm/ZuLCr ). The company ranked second worldwide in 12-lead ECG innovation among 243 firms analyzed, trailing only GE Healthcare. The recognition highlights HeartBeam’s growing influence in the next generation of cardiac monitoring technology.
Via Investor Brand Network · November 11, 2025